Mallinckrodt PLC

Mallinckrodt Plc engages in the development, manufacture, market, adn distribution of both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes innovative specialty pharmaceutical brands. The Specialty Generics segment relates to niche specialty generic drugs and active pharmaceutical ingredients. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mallinckrodt (MNK) delivered earnings and revenue surprises of 20.48% and -0.05%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Mallinckrodt (MNK) Q2 Earnings Beat Estimates

Mallinckrodt (NYSE: MNK) reported second-quarter earnings of $2.53 per share, which beat the analyst consensus estimate of $2.08 by 21.635.

Mallinckrodt Reports Q2 Earnings Beat

Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mallinckrodt (MNK) Reports Next Week: Wall Street Expects Earnings Growth

Mallinckrodt PLC (NYSE: MNK) shares are down 32.4% year to date, but a series of unusually large options trades Wednesday morning suggests at least one trader thinks there may be even more downside ahead.

Option Trader Makes Aggressive Bearish Play On Mallinckrodt

Mallinckrodt Pharmaceuticals plans to separate its business into two: one with its brand-name medicines; the other with its specialty generic drugs — including ooxycodone and hydrocodone.

One opioid drugmaker's solution to billions of potential liabilities: spin them out into new company

Worrisome information from a major opioid case appears to be weighing on the drug stock.

Why Mallinckrodt Stock Is Sliding Again Today

A lot of negative headlines surrounding Mallinckrodt, panic is clouding reality.

Mallinckrodt: A Lot Of Noise, But It's Not At All What It Looks Like

Another bump in the road for Acthar is weighing on the drugmaker.

Why Mallinckrodt Stock Is Sinking Today

Mallinckrodt (MNK) halts its phase IIB study, assessing the efficacy and safety of Acthar Gel as an investigational treatment for amyotrophic lateral sclerosis.

Mallinckrodt (MNK) Discontinues Sclerosis Study on Acthar Gel

Endo International

Teva Pharmaceutical

These drug developers are all valued at less than four times this year's projected earnings per share.

3 Drug Stocks With Unimaginably Low P/E Ratios

Bausch Health Companies Inc

Merck

Pharmaceutical and biotech stocks skidded Monday on expectations that President Donald Trump will sign an executive order to corral drug prices. This would be his 23rd executive order in 2019.

Medical Stocks Hammered As Trump Mulls Order To Corral Drug Prices

Mallinckrodt (MNK) closed the most recent trading day at $9.18, moving +1.89% from the previous trading session.

Mallinckrodt (MNK) Outpaces Stock Market Gains: What You Should Know

Mallinckrodt (MNK) reports encouraging results from a phase IV study on Acthar for RA at the EULAR.

Mallinckrodt Presents Encouraging Data on Acthar Gel for RA

Mallinckrodt (MNK) expects to pay $15.4 million to DOJ in relation with the Questcor litigation.

Mallinckrodt Down After Agreement with DOJ for Litigation

Emerging lawsuits and general sector correction caused a sharp price correction.

Mallinckrodt: Lawsuit Worries Massively Overblown

Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock?

Why Is Mallinckrodt (MNK) Down 47.4% Since Last Earnings Report?

Biopharmaceutical company Mallinckrodt plc (NYSE: MNK) said Wednesday it reached an agreement in principle with the Department of Justice relating to "legacy sales and marketing activites" by its Questcor subsidiary.

Mallinckrodt Agrees To Pay $15.4M In DOJ Settlement Over Acthar Subsidies

Shares of Mallinckrodt PLC MNK, -2.47% dropped 2.4% in afternoon trade Wednesday, after the biopharmaceutical company said it reached an agreement in principle with the U.D.

Mallinckrodt's stock falls after it expects to pay more than $15 million to resolve DOJ investigation

Mallinckrodt says it expects to pay $15.4 million to the DOJ to settle a drug bribery case.

Pharmaceutical company Mallinckrodt expects to pay $15 million to settle DOJ drug bribing probe

Applied Genetic Technologies

Anika Therapeutics

Axovant Gene Therapies Ltd

Mallinckrodt (MNK) will spin-off its Specialty Generics business to its shareholders.

Mallinckrodt to Spin Off Specialty Generics Unit, Shares Down

Mallinckrodt Plc MNK, +5.60% said Tuesday it is planning to spin off its specialty generics/active pharmaceutical ingredients business in the second half to its shareholders.

Mallinckrodt to spin off specialty generics business in second half

Mallinckrodt (MNK) declines after filing suit against HHS and CMS for the protection of Medicaid patient access to Acthar.

Mallinckrodt (MNK) Down After Filing Suit Against HHS and CMS

The Department of Justice recently picked up two allegations against Mallinckrodt for potential illegal sales and marketing practices.

Mallinckrodt: Assessing A Possible Turnaround

Mallinckrodt PLC (NYSE: MNK) announced Tuesday that it filed a lawsuit against the Department of Health and Human Services and Centers for Medicare and Medicaid Services, challenging the federal government's decision to have the company change the base date average manufacturer price used to calculate Medicaid drug rebates for Acthar gel.

Mallinckrodt Slumps After Filing Acthar Lawsuit, But BMO Says It Can Take The Hit

Biopharmaceutical company Mallinckrodt plc (NYSE: MNK)'s shares lost about 25 percent of their value Tuesday following news that the company filed suit against the Department Of Health And Human Services and Centers for Medicare and Medicaid Services to challenge the level of Medicaid rebates issued for its Acthar gel.

News for Mallinckrodt PLC Stock (MNK)